Baloxavir Marboxil

CAS 1985606-14-1

General Information

Baloxavir Marboxil API is a cap-dependent endonuclease inhibitor that impedes the growth and spread of influenza virus in its finished dose. Baloxavir Marboxil specifically targets and binds to the influenza polymerase acidic (PA) protein, inhibiting its CEN activity. This inhibition of PA endonuclease halts the replication of influenza virus mRNA, resulting in a reduction of viral load. It was approved for medical use both in Japan and in the United States in 2018.

About the API

Systematic name ({(12aR)-12-[(11S)-7,8-Difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-6,8-dioxo- 3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7- yl}oxy)methyl methyl carbonate
Trade name(s) Xofluza
Technology Synthetic
Molecular Formula C27H23F2N3O7S
Molecular Weight 571.55 g/mol
Physical properties White to yellowish
Therapeutic category Antiviral
Available formulations Oral Liquid Oral Solid